title: [Suppression of monocyte-macrophage activation by anti-CD4 therapy in patients with chronic polyarthritis].
abstract: Monoclonal anti-CD4 antibodies have been introduced into the treatment of rheumatoid arthritis. A depletion of CD4+ T-cells down to 8% of the origin level (p less than 0.0001) followed the antibody application. Moreover, there was a significant reduction of blood monocytes to 30% (p less than 0.001). A reduced lymphocyte proliferation induced by antigens or mitogens was found in parallel. Prior to treatment, monocyte-macrophage activation in rheumatoid arthritis was signified by an increased expression of HLA-class II antigens and the CD14 antigen, and by an increased production of neopterin and interleukin-1. Anti-CD4 treatment resulted in a significant reduction of elevated levels of neopterin, beta 2-microglobulin in serum as well as IL-1 production in vitro.
authors.affiliation: Institut für Klinische Immunologie und Rheumatologie, Medizinische Klinik III, Universität Erlangen-Nürnberg.
authors.forename: G
authors.initials: G
authors.lastname: Horneff
authors.forename: F
authors.initials: F
authors.lastname: Emmrich
authors.forename: J R
authors.initials: JR
authors.lastname: Kalden
authors.forename: G R
authors.initials: GR
authors.lastname: Burmester
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000096:biosynthesis; D015214:Antigens, Differentiation, Myelomonocytic / Q000096:biosynthesis; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D001708:Biopterins / Q000031:analogs & derivatives / Q000096:biosynthesis; D015704:CD4 Antigens / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D007958:Leukocyte Count; D018950:Lipopolysaccharide Receptors; D008213:Lymphocyte Activation; D008262:Macrophage Activation / Q000276:immunology*; D009000:Monocytes / Q000276:immunology*; D019798:Neopterin; D001613:beta 2-Microglobulin / Q000096:biosynthesis
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015704:CD4 Antigens; D000949:Histocompatibility Antigens Class II; D007375:Interleukin-1; D018950:Lipopolysaccharide Receptors; D001613:beta 2-Microglobulin; D001708:Biopterins; D019798:Neopterin
vernacular_title: Suppression der Monozyten-Makrophagen-Aktivierung durch anti-CD4-Therapie bei Patienten mit chronischer Polyarthritis.